COGT – cogent biosciences, inc. (US:NASDAQ)
Stock Stats
News
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Form 10-Q Cogent Biosciences, Inc. For: Sep 30
Form 8-K Cogent Biosciences, Inc. For: Nov 12
Form SC 13G/A Cogent Biosciences, Inc. Filed by: FMR LLC
Form SC 13G/A Cogent Biosciences, Inc. Filed by: FMR LLC
Form 4 Cogent Biosciences, Inc. For: Oct 01 Filed by: Ferrante Karen Jean
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.